Tamsulosin
- Generic Name
- Tamsulosin
- Brand Names
- Flomax, Jalyn
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5S
- CAS Number
- 106133-20-4
- Unique Ingredient Identifier
- G3P28OML5I
- Background
Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.
Tamsulosin was first approved by the FDA on April 15, 1997.
- Indication
Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.
Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus
- Associated Therapies
- -
Hernia Surgery Urinary Retention
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- Memorial Health University Medical Center
- Target Recruit Count
- 140
- Registration Number
- NCT03027115
- Locations
- 🇺🇸
Memorial Health University Medical Center, Savannah, Georgia, United States
Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair
- Conditions
- Postoperative Urinary Retention
- Interventions
- Drug: TamsulosinDrug: Placebo Oral Capsule
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Ascension Health
- Target Recruit Count
- 210
- Registration Number
- NCT02958878
Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery
- Conditions
- Post-operative Urinary Retention
- Interventions
- Drug: PlaceboDrug: Tamsulosin
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Anand Rughani, MD
- Target Recruit Count
- 610
- Registration Number
- NCT02919436
- Locations
- 🇺🇸
Maine Medical Center, Portland, Maine, United States
Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia
- Conditions
- Benign Prostate Hyperplasia
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 588
- Registration Number
- NCT02827578
- Locations
- 🇰🇷
Samsung medical center, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
- Conditions
- Benign Prostatic HyperplasiaOveractive Bladder
- Interventions
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 715
- Registration Number
- NCT02757768
- Locations
- 🇺🇸
Site US01009, Homewood, Alabama, United States
🇺🇸Site US01005, Huntsville, Alabama, United States
🇺🇸Site US01070, Hawaiian Gardens, California, United States
Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
- Conditions
- Lower Urinary Tract SymptomsOveractive BladderBenign Prostatic Hyperplasia (BPH)
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Astellas Pharma Taiwan, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02715024
- Locations
- 🇨🇳
Site, Taipei, Taiwan
Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention
- Conditions
- Post-Operative Urinary Retention
- Interventions
- Drug: TamsulosinOther: Education
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 5
- Registration Number
- NCT02684344
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 568
- Registration Number
- NCT02656173
- Locations
- 🇯🇵
Site JP81043, Fukuoka, Japan
🇯🇵Site JP81048, Fukuoka, Japan
🇯🇵Site JP81003, Hokkaido, Japan
Actual Use Study of Tamsulosin in Men
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1117
- Registration Number
- NCT02573311
- Locations
- 🇺🇸
Kroger Pharmacy #342, Cary, North Carolina, United States
🇺🇸Garden Drug, Fort Lauderdale, Florida, United States
🇺🇸Eagle Pharmacy, Houston, Texas, United States
Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients
- Conditions
- Postoperative Urinary Retention
- Interventions
- Drug: TamsulosinDrug: Placebo
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 176
- Registration Number
- NCT02518971
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.